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Diabetes is a metabolic disorder that is characterized by high blood glucose con-
centrations resulting from insulin deficiency in case of type 1 or insulin inefficiency in
case of type 2. While no cure for diabetes exists, the artificial pancreas is a possible
way to manage diabetes, especially for type 1 diabetics. Where an artificial pancreas is a
closed loop control system with an integrated mathematical model. This control system
imitates the function of a healthy pancreas. The first part of this thesis is concerned with
the control system of an artificial pancreas that is based on Bergman’s minimal model of
the glucose-insulin dynamics. The aim of the first part of this thesis is to prove both the
controllability and the observability of the minimal model which is an fundamental step in
the design of an optimal control system. These proofs are based on several mathematical
tools such as the insertion of time delays, and theorems such as the Banach contraction
mapping theorem in addition to the results of previous related works.
On a different note, COVID-19 is a highly infectious global pandemic that tar-
gets the respiratory system. The symptoms of this disease were found to be more severe
towards patients with comorbidities including diabetes, and so, the second part of this the-
sis is concerned with the relation of COVID-19 with comorbidities, where a COVID-19
disease transmission model that focuses on comorbidity populations is presented. This
model aims at determining the major factors that contributes to the transmission of this
disease. The results of this model can aid in implementing strategies that can help in con-
trolling the spread of this pandemic. Parameter estimations of the model are presented in
addtion to several related calculations including the basic reproduction number and the
sensitivity indices of the model’s parameters.
Keywords: Diabetes, Control systems, Controllability, Observability, COVID-19, Com-
partmental disease transmission models, Sensitivity index, Basic reproduction number.
 
Title and Abstract (in Arabic) 
 
على مرضى  19-كوفيدو تأثير  و قابلية مراقبته مستوى الجلوكوز بالدمبالتحكم  القدرة على
 السكري
صف بارتفاع مستوى الجلوكوز بالدم الناتج عن يت مرض السكري هو اضطراب في عملية األيض  الملخص
عدم كفاءة اإلنسولين في النوع الثاني. في حين اليوجد  نقص مستوى اإلنسولين في حالة النوع األول أو
ً لمرضعالج لمرضى السكري، يعتبر البنكرياس الصناعي طريقة ممكنة   ىإلدارة المرض و خصوصا
ّرف البنكرياس الصناعي على أنه نظام تحكم مغلق قائم على نموذج رياضي عي  و السكري من النوع األول. 
م بنظا يهتماألطروحة  من هذه الجزء األول اكاة وظيفة البنكرياس السليم.يعمل هذا النظام على مح معين.
 برجمان البسيط كنموذج رياضي خاص بديناميات يستخدم نموذج الذي صناعيالبنكرياس الخاص بالتحكم ال
الهدف من الجزء األول من هذه األطروحة هو إثبات كالً من إمكانية التحكم و إمكانية  .الجلوكوز و اإلنسولين
المقدمة  مراقبة المتعلقة بنموذج برجمان البسيط و هي خطوة أساسية في تصميم نظام تحكم أمثل. البراهينال
 ذج و نظريات مثلة على عدة أدوات رياضية مثل إدراج التأخيرات الزمنية في النمونيفي هذه األطروحة مب
ج. ه جائحة عالمية شديدة العدوى تستهدف النظام التنفسيبأن 19-كوفيدعرف من ناحية أخرى، ي     صلة.النظرية النقطة الثابتة لباناخ باإلضافة إلى نتائج األعمال السابقة ذات  د و 
بما في ذلك مرض ة أعراض هذا المرض تبدو أكثر حدة تجاه المرضى الذين يعانون من أمراض مصاحبأن 
حيث  باألمراض المصاحبة 19-كوفيدثاني من هذه األطروحة بعالقة مرض ك يهتم الجزء الالسكري. ولذل
ألمراض المصاحبة. باالذي يركز على السكان المصابين  19-تم تقديم نموذج انتقال المرض الخاص بكوفيد
هذا قدمها التي ينتائج الهذا المرض.  شارانتالعوامل الرئيسية التي تساهم في يهدف هذا النموذج إلى تحديد 
في السيطرة على انتشار هذا المرض. هذا الجزء من  تساهمالنموذج قد تساعد في انشاء االستراتيجيات التي 
النموذج باإلضافة إلى حسابات ذات صلة مثل عدد الخاصة بمعامالت الاألطروحة يحتوي على تقدير قيم 
 سية المعامالت الخاصة بالنموذج.   التكاثر األساسي و موشر حسا
، 19-القدرة على التحكم، قابلية المالحظة، كوفيدمرض السكري، أنظمة التحكم، : ةيمفاهيم البحث الرئيس
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Chapter 1: Introduction
1.1 Description of Diabetes
Diabetes is a chronic disease characterized by high blood glucose levels resulting
from the body’s inability to produce insulin or insufficient insulin production. It can also
be a result of the body’s incapability of efficient insulin usage [1, 2]. In other words,
Processes that can lead to the development of diabetes ranges from the destruction of the
insulin producing beta cells in the pancreas by the immune system resulting in insulin
deficiency to the abnormalities that results in insulin resistance [1].
1.2 Diabetes Complications
People with diabetes are at high risk of developing some long-term complica-
tions resulting from the prolonged periods of high blood glucose. These complications
can effect different body organs including the eyes, kidneys, nerves, heart, blood vessels,
and limbs [1, 3]. Possible eye complications resulting from diabetes includes blurring,
cataracts, and blindness. Cataracts for instance is caused by glucose accumulation in
the lenses of the eyes which eventually obstructs light transmission to the back of the eye
causing the lenses to be opaque [3]. Since Kidneys are responsible for filtering blood, kid-
ney damage might also be accompanied with diabetes. This is caused by filtering blood
with high glucose levels which in turn damages the tiny blood vessels in the kidneys [3].
Other diabetes complications includes nerve damage, limb amputation, stroke, cardio-
vascular diseases and high blood pressure [3]. These complications could be avoided if
diabetes is properly managed and dealt with [2]. Figure 1.1 illustrates possible diabetes
complications on the different body parts.
2
Figure 1.1: Diabetes complications
1.3 Types of Diabetes
Diabetes is commonly categorized into type 1 and type 2 diabetes. Type 1 dia-
betes is an autoimmune disease in which the immune system of the body attacks the beta
cells that produces insulin leading to insufficient or no insulin production. On the other
hand, type 2 diabetes is a result of what is known as insulin resistance, where the body
cells are unable to fully react to insulin. Insulin is ineffective during the insulin resistance
state. As a result, insulin is overly produced and over time the beta cells of the pancreas
fails to keep up with the demand resulting in insufficient insulin production [1, 2]. Type
2 diabetes is more common as it accounts for 90% of diabetes cases [2].
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1.4 Glucose-Insulin Regulatory System
The normal blood glucose concentration is within the range 70 – 110 mg/dl. The
insulin and glucagon hormones which are secreted from the pancreatic beta and alpha
cells respectively are responsible for maintaining blood glucose homeostasis as presented
in Figure 1.2 [4]. Insulin hormone is released when the blood glucose concertation is
high stimulating excess glucose uptake by the muscle, fat and liver cells and restraining
hepatic glucose production which results in lowering the blood glucose concertation. On
the other hand, glucagon hormone is released when the blood glucose concentration is low
stimulating the conversion of the glycogen stored in the liver into glucose which results
in increasing the blood glucose concentration [4].
Figure 1.2: Blood glucose regulation
In case an individual’s blood glucose concentration is continuously outside the
normal range, then the individual is considered to have either hyperglycemia (glucose
excess in bloodstream) or hypoglycemia (glucose deficiency in bloodstream). Diabetes
mellitus is a disease characterized by hyperglycemia [4].
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1.5 Prevalence of Diabetes
1.5.1 Worldwide
Diabetes is widely spread in the world given that the estimated number of the
adult diabetic individuals aged 20 – 79 years worldwide was about 463 million in 2019
making up to 9.3% of the total adult population with type 2 accounting for nearly 90%
of the diabetes cases. The number of diabetics is expected to increase to 578.4 million
worldwide by 2030, in case the current trend continues [2]. Moreover, according to an
estimate made in 2019 it was found that high-income countries have the highest preva-
lence of diabetes in adults of about 10.4% followed by middle-income countries with
prevalence of 9.5%. On the other hand, low-income counties had the lowest prevalence
of almost 4% [2].
Figure 1.3: Estimated prevalence of diabetes in adults in 2019
Figure 1.3 (obtained from [2]) gives an illustration of the estimated prevalence of
adults aged 20 – 79 years with type 1 and type 2 diagnosed and undiagnosed diabetes in
the world map. Looking at the map one can clearly deduce that the Middle Eastern and
North African regions are highly prevalent with diabetes.
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1.5.2 MENA Region/Arab world
Diabetes is notably prevalent in the Middle Eastern and North African (MENA)
region. In this region, it was estimated in 2019 that nearly 54.8 million adults aged 20 to
79 years have diabetes, which makes up to 12.8% of the total population. This prevalence
percentage of 12.8% is considered the highest among the other world regions classified
by the International Diabetes Federation (IDF) [2]. This region have the second-highest
rate of increases in diabetes in the world [5].
There is a clear rise in type 2 diabetes mellitus in the Arab world of the MENA
region. In fact, According to the IDF three Arab countries were among top ten countries
in the prevalence of type 2 diabetes mellitus in 2013, namely, Saudi Arabia, Kuwait, and
Qatar [5]. The high prevalence of type 2 diabetes mellitus in the Arab world can be a
result of some risk factors that includes genetic factors which cannot be controlled and
other modifiable risk factors such as obesity which is associated with eating habits and the
lack of physical activity in addition to rapid urbanization [5]. Obesity is closely linked to
type 2 diabetes as evidenced by many studies. For instance, a study was made in Kuwait
with 1970 subjects of both genders found that 47.7% of obese males and 77.3% of obese
females were diabetic [6]. Another study made in Saudi Arabia with 1385 male subjects
found that 65% of diabetic patients were overweight [7]. Additionally, a study from Qatar
of 1434 subjects found that 59.7% of diabetics were obese [8]. These studies serves as a
great evidence of the correlation between type 2 diabetes and obesity.
Obesity is highly prevalent in the Arab world as evidenced by many studies and
reports including a report made by the World Health Organization (WHO) in 2014 [9].
This report presented obesity percentages of adults in different countries of the world
based on data from 2010. This report revealed that obesity is highly prevalent in Arab
countries, especially in countries of the gulf region [9]. It stated that 55% and 30% of
females and males respectively are obese in Kuwait. It also stated that 42% of females
and 25% of males are obese in the UAE [9]. Since obesity is highly prevalent in the Arab
world it would not be surprising for type 2 diabetes mellitus to be prevalent as well given
6
that the two are correlated.
The high incidence of obesity in the Arab world is mostly contributed by the fol-
lowed dietary habits. This is pointed out by a study made on the dietary habits of some
countries in the MENA region [10]. The analysis of this study suggested that many coun-
tries in the MENA region follow a diet that has low intake of fruits, vegetables and whole-
grains and high intake of red and processed meats as well as foods high with sodium. Such
dietary habits justifies weight gain and obesity [10]. Another factor that contributes to the
spread of obesity in the Arab world is the inactive lifestyle that most Arabs adapt. This
is demonstrated by a study made to assess physical activity in Arab countries [11]. This
study concluded that the prevalence of physical inactivity exceeds 40% in almost every
Arab country [11]. These factors that leads to obesity are usually associated with rapid
urbanization as suggested by the prevalence rates of type 2 diabetes, where prevalence
rates are much higher in urbanized countries compared to rural ones [5].
1.5.3 The United Arab Emirates
The United Arab Emirates has undergone a rapid development in the economy
during the last two decades. This development had a positive influence in the country’s
educational and medical sectors. It has also led to increased prosperity. However, there
is a downside to this development as there is a decrease in the physical activities as the
lifestyle has become more sedentary. In addition, there is an increase in food intake
along with bad dietary habits. These downsides has led to an increase in the prevalence of
obesity together with type 2 diabetes mellitus [12]. In 2017, the IDF stated that the UAE is
considered the second highest country in the percentage of age adjusted diabetes of adults
in the MENA region with a percentage of 17.3% making up to 1185500 diabetes patients.
The IDF also revealed that the number is expected to increase in case no intervention
takes place [13].
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1.6 Economical Facts of Diabetes Worldwide
Between direct medical costs of diabetes detection and treatment and indirect
costs of absence or underperformance of diabetic workers, diabetes and its complications
are a great burden to the national economies especially since diabetes complications are
either long-term, severe or both [2, 4]. A study was made to estimate the global economic
burden of diabetes in adults aged 20 – 79 years in 2015. In this study data were collected
from 184 countries where direct diabetes costs were based on health expenditure data
provided from the WHO and prevalence data provided from the IDF and indirect diabetes
costs were estimated by assuming a human-capital approach were diabetes related mor-
bidity and mortality were considered [14]. It was found that diabetes global economic
burden accounts for about US$1.31 trillion with 34.7% credit to indirect costs [14].
1.7 COVID-19 and Diabetes
Corona Virus Disease 2019 (COVID-19) is a global viral disease that targets
the respiratory system. What is concerning about this disease is that it is highly trans-
missible as it can be transmitted not only through direct contact of infected surfaces or
droplets released from the infected, but it can also be transmitted through inhalation. The
symptoms of this disease are mild for most patients, however, infected people with co-
morbidities such as diabetes and cardiovascular diseases are at a higher risk of developing
severe symptoms such as multi organ failure or even fatality [15]. A study of COVID-19
patients who were critically ill was carried out in Wuhan, china. Among 52 intensive
care unit (ICU) patients it was found that 22% of 32 non survivors were diabetic [16].
Another study found that 12% among 120 critically ill COVID-19 patients were diabetic
[16]. Furthermore, it has been evidenced that diabetic patients who were infected with
any of the earlier corona viruses, namely, Severe Acute Respiratory Syndrome (SARS) or
Middle East Respiratory Syndrome (MERS) had worse disease complications and higher
mortality rates [17]. These studies suggests that having diabetes increases the severity of
COVID-19 and its related fatality rates.
8
Chapter 2: Bergman’s Minimal Model
2.1 The Origin of Bergman’s Minimal Model
Over the years mathematical models have been used to describe the behavior of
many different physiological systems. Many models were dedicated to investigate the
blood glucose regulatory system in form of a system of differential equations, and these
models varied from simple to complex [18]. Early models of the glucose-insulin dynamics
were doubted and had a very limited role in the diagnosis and treatment of diabetes. This
is caused by the unfamiliarity of using mathematical modeling to describe a closed-loop
feedback physiological system [18]. Another reason was that organs which has a primary
role in regulating the blood glucose concentration has non-linear functions by nature,
given the fact that non-linear systems are unpredictable and difficult to solve [18, 19].
The characteristics of the beta cells, responsible for producing insulin, are consid-
ered complex, especially since it secretes insulin in two phases [18]. The first secretion
phase starts after nutrient consumption and lasts for about 10 minutes, whilst the second
phase is sustained until blood glucose concentration is within the normal range [20]. As
a result, it is quite difficult to have a simple mathematical representation of the beta cells’
function [18]. In order to overcome these complexities and efficiently use mathemati-
cal modeling to investigate the regulation of the blood glucose concentration, Bergman
[21] utilized the Intravenous Glucose Tolerance Test (IVGTT) to form his model were
he frequently measured plasma glucose and insulin of a group of test subjects following
injecting them with a dose of glucose to see how plasma glucose interacts with insulin
[18, 21].
The original purpose of the minimal model was to quantify the contribution of the
responsivity of the beta cells to glucose (insulin secretion) and the sensitivity of the body
tissues to the secreted insulin (insulin sensitivity) to the glucose tolerance. Where glucose
tolerance can be defined as the body’s ability to clear the blood from glucose [21].
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2.2 The Intravenous Glucose Tolerance Test
The IVGTT is a clinical test that is used to determine the body’s ability to me-
tabolize glucose. At the beginning of this test venous fasting blood sample is obtained,
thereafter, 25gm of glucose is injected intravenously during a period of two minutes, and
within the next two hours samples of venous blood are continuously obtained and the last
of which is used to decide whether the person has diabetes or not. That is if the blood
glucose concentration is above 120 mg/dl, then the tested person has diabetes mellitus.
Whereas if the blood glucose concentration is less than 100 mg/dl, then the tested person
is most likely not diabetic. In case the glucose concentration lies in the range 100 – 120
mg/dl, then the test result is undefined [22].
2.3 Bergman’s Minimal Model
Despite the existence of many models that describes the glucose-insulin dynam-
ics, the Bergman minimal model is considered the simplest model that is useful and both
efficient and accurate. This model is given by the following system of Ordinary Differen-
tial Equations (ODEs) [23]:
Ġ = −p1(G−Gb)−GX
Ẋ = −p2X + p3(I− Ib)
İ = −n(I− Ib)+ γ[G−h]+t +u(t)
(2.1)
Where the state variables:
G: represents the plasma glucose concentration in mgdl .
X : represents the effect of the active insulin on the glucose concentration in min−1.
I: represents the plasma insulin concentration in µUml .
The constants Gb and Ib represents the basal values of the plasma glucose and insulin
concentrations, and the Insulin infusion rate is represented by u(t).
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As for the parameters [23]:
p1: is the insulin-dependent glucose disappearance rate in min−1.
p2 is the natural decrease rate of the ability of tissues to absorb glucose in min−1.




Figure 2.1 and Figure 2.2 demonstrates the minimal model’s glucose and insulin dynamics
respectively:
Figure 2.1: Minimal model of glucose disappearance
Figure 2.2: Minimal model of insulin kinetics
2.4 Cobeli’s Model
A More comprehensive nonlinear model that includes the dynamics of the glucagon
hormone is built by Cobelli [24]. This model is composed of three subsystems that de-
scribes the dynamics of the glucose, insulin and glucagon [24].
A single compartment is used in the glucose subsystem, this compartment describes the
distribution and metabolism of glucose. It involves the balance of the liver’s glucose pro-
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duction and consumption, kidney’s blood glucose filtration, the insulin dependent glucose
utilization which is mainly done by the muscle and fat cells, in addition to the independent
glucose utilization performed by the brain and nerve cells [24].
The insulin subsystem is composed of five compartments representing: insulin
stored in the pancreas, instantly released pancreatic insulin, insulin in the plasma, insulin
in the liver and insulin in the interstitial fluid (fluid presented in the small gaps between
the body cells) [24, 25]. The glucagon subsystem is including a single compartment that
involves the glucagon in the plasma and interstitial fluids [24].
The main purpose of this model was to investigate the interaction between glucose
and insulin during the states of hyperglycemia. This model has been validated on both
normal and pathological conditions, and it has been employed in researches that involves
the regulation of carbohydrate metabolism [24].
2.5 More Extensions
Bergman’s model has been widely used in the development of many blood glu-
cose regulation models and other related applications. In fact, Bergman himself used his
minimal model to develop a computer program that measures the insulin sensitivity, glu-
cose effectiveness (glucose’s own disappearance ability) along with the first and second
phases of pancreatic responsivity [26].
Despite the usefulness and the many applications of Bergman’s minimal model,
it received many criticism [27]. The majorly criticized shortcomings of this model were
the model’s incoherence and lack of robustness in the procedure of parameter identifi-
cation [27]. This is coming from the procedure that was performed to fit the model’s
parameters. The procedure was done in two steps. Firstly, recorded insulin concentration
was regarded as an input to derive the glucose dynamics parameters. Secondly, recorded
glucose concentration was regarded as an input to derive parameters of the insulin dynam-
ics [28]. The two step parameter identification procedure decouples the glucose-insulin
system even though, physiologically this system is a unified and an integrated feedback
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system. Consequently, this is considered a limitation of Bergman’s model [27, 28].
In order to overcome these shortcomings and furtherly improve the minimal model,
many extended and modified versions of Bergman’s model were proposed. One of those
models [28] considered a single step parameter identification procedure and excluded the
remote compartment presented in the minimal model resulting in a more coherent model.
This model was also furtherly improved and modified.
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Chapter 3: Literature Review - Mathematical Control Theory
3.1 Linear Control Systems
A linear control system can be described by the following system of ODEs [29, 30]:
 ẋ = A(t)x+B(t)ux(t0) = x0 (3.1)
Given the following assumptions:
1. x(t) ∈ Rn, and is both real and continuous and satisfies equation (3.1).
2. A(t) ∈Mn×n, B(t) ∈Mn×m, and both of which are bounded and real.
3. In such a system, a controller u(t) ∈ Rm is selected so that it steers x(t) from an
initial state x0 at t0 to a desired state xd at t1. Given that u(t) is real and bounded on
the interval [t0, t1] and assuming values from a non-empty set Ω ⊆ Rm.
The solution of such a linear system is given by [29]:




Where Φ(t) is the fundamental matrix solution of the homogenous non-controlled linear
system:
ẋ = A(t)x (3.3)
In other words, Φ(t) is an n×n matrix whose columns are the linearly independent solu-
tions of (3.3) with Φ(t0) = I. Moreover, if A(t) is a constant A, then Φ(t) = eA(t−t0).
14
3.2 Autonomous Linear Control systems
Autonomous linear control systems are the ones in which the rate of change of the
state variables with respect of time ẋ does not depend explicitly on the time t.
Consider an autonomous linear control system with the following representation [29]:
ẋ = Ax+Bu (3.4)
In this system x ∈ Rn. Matrix A ∈ Mn×n and matrix B ∈ Mn×m, and both of which are
real, constant valued matrices.
3.2.1 Controllability
In control theory, Controllability is regarded an essential attribute of a control
system as it must be satisfied in order to achieve the desired controlling goal. The system
defined by equation (3.4) with unrestrained control values (i.e. u(t) ∈ Ω = Rm) is said to
be completely controllable in case for any two states x0 , x1 ∈ Rn, there exists a controller
u(t) that steers x0 to x1 in a finite time [29, 30].
3.2.1.1 Controllability Test
Kalman’s rank condition: One way to determine whether the linear system in
hand is controllable or not is by finding the rank of the controllability matrix, which is an
n×nm matrix of the following form [29, 30]:
C = [B,AB,A2B, ...,An−1B]
Then, the system is controllable if and only if rank(C) = n.
Controllability operator: Another method to check the controllability of a linear
control system defined on an interval [t0, t1] is to check the range of its corresponding
controllability operator G, then:
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Linear control system is controllable⇔ Range(G) = Rn
Where the controllability operator for this control system
G : L2(t0, t1;Rm)−→ Rn





Other methods to test the controllability of an autonomous linear system are presented in
[29] along with its proofs.
3.2.2 Observability
A control system is observable if observations or measurements of the output over
a finite time interval provides enough information to determine the internal states of the
system. In other words, if knowledge of the output y(t) on any time interval [t0, t1] allows
the computation of the initial state of the system x(t0) = x0, then the system is observable
[29, 30].
The observability equation for the linear system in (3.4) is given by [29, 30]:
y(t) = Hx(t) (3.5)
Where y(t) ∈Rr represents the observable output, and H ∈Mr×n is a real constant matrix.
3.2.2.1 Observability Test
Kalman’s rank condition: Determining whether the linear system defined by equa-
tions (3.4) and (3.5) is observable or not can be done using the Observability matrix which
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Then, the system is observable if and only if rank(O) = n.
Observability operator: Another possible way to check the observability of a
linear control system defined on an interval [t0, t1] is to check the observability operator
µ , where
Linear control system is observable⇔ µ is one-to-one.
Where the observability operator for this control system
µ : Rn −→ L2(t0, t1;Rr)
is defined as follows,
µ(z) = HeA(.)z
Other methods to test the observability of an autonomous linear control system are pre-
sented in [29] along with its proofs.
3.2.3 The Duality Property
Observability and controllability are related in linear systems as they have a dual-
ity between them as proposed by the following theorem [29]:
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Theorem 3.2.1. The autonomous linear observed control system given by
ẋ = Ax+Bu, y(t) = Hx (3.6)
is observable if and only if the dual system given by
ẋ = AT x+HT u, y(t) = BT x (3.7)
is controllable.











Since the transpose of any matrix has the same rank as the original one then,
rank
[
HT , AT HT , ... ,(AT )n−1HT
]
= n
Which applies that a linear system defined by (3.7) is controllable and vice versa.
3.3 Optimal Trajectory Tracking
Trajectory tracking aims to lead the state trajectories x(t) ∈ Rn of a dynamical
system to track a desired reference trajectory xd(t) ∈ Rn that is defined over an interval
[t0, t1]. In this case, the closer x(t) is to xd(t) the better the controlling goal is achieved.
Ideally, x(t) = xd(t) at all times t > 0 [31].









Optimal trajectory tracking aims to minimize the distance between x(t) and xd(t).
This is done by finding a control u(t) ∈ Rm that minimizes J [x(t)] such that other con-
trollers results in larger distances between x(t) and xd(t).
Equation (3.8) might lead to an ill-defined u(t) and x(t) functions, so a possible way to fix













The additional term in (3.9) ensures a well defined solution and avoids large controls.
However, in most biological control systems the control u(t) ∈ Ω where Ω is a restrained
subset of Rm. This restrain depends on the biological nature of the control. Therefore, the
additional term in equation (3.9) is removed and the equation is reduced back to equation
(3.8) since the main goal of the control system in this case is to track xd .
3.4 Semilinear Control Systems
A semilinear control system can be described by the following system of ODEs [32]:
 ẋ = A(t)x(t)+B(t)u(t)+ f (t,x(t),u(t)) , t ∈ (t0, t1]x(t0) = x0 (3.10)
Given the following assumptions:
1. x(t) ∈ Rn, u(t) ∈ Rm.
2. A(t) and B(t) are continuous real matrices with A(t) ∈Mn×n and B(t) ∈Mn×m.
3. u(t) ∈ L2([t0, t1];Rm).
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4. f : [t0, t1]×Rn×Rm→ Rn is continuous.
3.4.1 Approximate Controllability of a Semilinear System
Definition 3.4.1. The semilinear system (3.10) is said to be approximately controllable
on an interval [t0, t1], if for any ε > 0, initial state x0 ∈ Rn, and final state x1 ∈ Rn there
exists a control u ∈ C([t0, t1];Rm) such that the corresponding solution of system (3.10)
satisfies the following condition [33]:
‖x(t1)− x1‖< ε
3.4.2 Exact Controllability of a Semilinear System
Definition 3.4.2. The semilinear system (3.10) is said to be exactly controllable on an
interval [t0, t1] if for any initial and final states x0,x1 ∈ Rn, there exists a control u ∈
C([t0, t1];Rm) such that the corresponding solution of system (3.10) satisfies [33]:
x(t0) = x0, x(t1) = x1
3.4.3 Observability of a Semilinear System
Definition 3.4.3. A semilinear system of the form (3.10) along with an observation:
y = Hx
is said to be observable on an interval [t0, t1], if any pair of observation and control (y,u)
uniquely determines the initial condition of the system. In other words, for two solutions
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of (3.10) x1(t) and x2(t), if




Chapter 4: Artificial Pancreas and Diabetes
4.1 Problem Statement
As stated in Chapter 1, the normal fasting blood glucose concentration ranges
between 70 mg/dl to 110 mg/dl. People with type 1 or type 2 diabetes have blood glucose
concentrations that exceeds the normal range for prolonged periods of time. A possible
way to manage diabetes mellitus, especially type 1 is the artificial pancreas, which is a
closed-loop control system that regulates the patient’s blood glucose level. This system
consists of a continuous blood glucose monitoring sensor (CGM), a control algorithm
and an external insulin pump [34]. The CGM measures the patient’s blood glucose level
and sends the measurement to a small computer that acts as a moderator between the
CGM and the insulin pump. This computer then calculates the required amount of insulin
to maintain the blood glucose concentration within the normal range based on a built-in
control algorithm. Followingly, the computer sends a signal of the calculated amount
to the external insulin pump to inject the patient with the calculated amount. This way
the artificial pancreas imitates the function of a healthy individual’s pancreas. Figure 4.1
shows a block diagram of the function of an artificial pancreas.
Figure 4.1: Block diagram of an artificial pancreas
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A mathematical model of the blood glucose regulatory system is required to in-
tegrate the CGM to the insulin pump in an artificial pancreas. Furthermore, since the
artificial pancreas is a control system, where the controlled variable is the blood glucose
concentration and the control input is the external insulin infused through the pump. then,
the patient’s blood glucose concentration can only be regulated when the artificial pan-
creas is both controllable and observable. The aim of this part of the thesis is to prove
both the controllability and observability of an existing artificial pancreas control design.
4.2 Existing Approach
An existing feedback and feedforward controller design for an artificial pancreas
is presented in [35]. In this design the mathematical model used to describe the dynamics
of the plasma insulin and glucose is the Bergman’s minimal model. Since the parameters
of the model differ slightly amongst people, the model was slightly altered to include
parameter uncertainties so that the artifical pancreas can be tailored to fit a wide range of
people [35].
In [35] an exogenous glucose input J from food that passes through the intestines
is included. Moreover, it is assumed that the reference/desired glucose R as well as the
exogenous glucose J are time-varying. Furthermore, the designed controller is both feed-
back and feedforward. The feedback part uses the actual blood glucose concentration G
as an output whereas, the exogenous glucose J and the desired glucose R are regarded as
disturbances for the feedforward part. Then, the controller u = u(G,R,J) is designed such
that it tracks the desired glucose for any slight parameter variations. The flow diagram of
the feedback and feedforward controller is presented in Figure 4.2.
The version of the minimal model that has been used in [35] without parameter uncertain-
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Figure 4.2: Flow diagram of feedback and feedforward controller
ties is described by the following nonlinear system of ODEs:

dG
dt = −m1G−XG+ J
dX
dt = −m2X +m3I
dI
dt = −m4I +u
(4.1)
Designing the controller involved using several mathematical tools including the Fourier
series polynomials, the center manifold theory, variable transformations and more. to
learn more check the main reference [35].
4.2.1 Results and Problems of Approach
The main aim of [35] was to design a feedback and feedforward controller u =
u(G,R,J) such that the actual blood glucose concentration G which is the controlled vari-




In order to test the efficiency of the designed controller, numerical simulations
were performed using a 24 hour insulin and glucose profiles of a group of normal men
obtained from the experiment published in [36]. The simulated controlled glucose con-
centration G and the tracked glucose reference R obtained from [36] are plotted together
in the following figure (obtained from [35]).
Figure 4.3: Glucose tracking under robust controller
Figure 4.3 shows that the designed controller succeeded in achieving its goal since
clearly the controlled glucose concentration asymptotically tracks the reference glucose.
4.2.1.2 Problems
Even though the tracking goal of the controller in [35] was achieved, a problem




The problem with this formulation is that the time t that is needed for G to track R
could range from a couple of hours to a few days or even weeks. In other words, there is
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no time restriction, which is a problem considering that this is a biological problem that
involves a diabetic patient. The issue here is that it might take days before G could track
R. Accordingly, G could have a very high oscillations that can damage the patient’s organs
and cause him some serious health issues that could eventually lead to the development
of some long term complications. Moreover, many diabetics turn off their artificial pan-
creas when sleeping, which furtherly emphasize the importance of having an appropriate
working time frame for the artificial pancreas. As a result, this approach is not practical.
Therefore, it is better to consider a more realistic approach when addressing the issue of
blood glucose regulation. Moreover, the controllability and observability of the artificial
pancreas where not checked even though it is an essential step in control design.
4.2.2 Contribution of Thesis and Possible Future Work
Firstly, since [35] did not include any controllability or observability proofs. The
first part of this thesis is dedicated to prove the controllability and the observability of the
Bergman model presented in [35] without the inclusion of the parameter uncertainties.
Secondly, a possible future work that could improve what was made in [35] is to
find an optimal control u such that the output G(t) = R(t) at all times t > 0. Achieving this
goal seems possible using the Trajectory Controllability approach which is also known as
T-Controllability were the aim is to look for a controller that steers the state variable
trajectories of a system along a specified trajectory instead of steering the state variables
from an initial state to a desired final one [37].
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4.3 Proofs of the Controllability and the Observability
In the presented proofs it is assumed that the exogenous glucose input J in system
(4.1) is also a control variable in addition to u. This assumption was based on the fact
that the glucose input can be controlled through the management of the dietary habits.





Then, model (4.1) can be presented in the following semilinear form:
ż(t) = Az(t)+Bv(t)+F(z), t ≥ 0 (4.2)
Along with the observation


























Before looking into the controllability of system (4.2), it is necessary to study the control-
lability of the corresponding linear system of ODEs:
ż(t) = Az(t)+Bv(t), t ∈ (t0,τ]
z(t0) = z0
(4.4)
Proposition 4.3.1. System (4.4) is exactly controllable on any interval [t0,τ], with t0 < τ .
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And by reducing matrix C, it is found that Rank(C) = 3 =⇒ the linear system (4.4) is
controllable on any time interval [t0,τ], with t0 < τ.
4.3.1 Approximate Controllability
In order to help prove the approximate controllability of system (4.2) a time delay
of r is introduced in the term of non-linearity to get the following system:
dG
dt








Along with the following initial conditions:
G(s) = φ1(s), s ∈ [−r,0]
X(s) = φ2(s), s ∈ [−r,0]
I(s) = φ3(s), s ∈ [−r,0]
Where φ1(s), φ2(s) and φ3(s) are functions of the historical data of each state variable.
System (4.5) along with its initial conditions can be represented compactly as follows:
ż(t) = Az(t)+Bv(t)+F(zt(−r)), t ≥ 0
z(s) = φ(s), s ∈ [−r,0]
(4.6)
where the function zt : [−r,0]→ R3 is defined by:
zt(s) = z(t + s)
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Definition 4.3.1. System (4.6) is said to be approximately controllable on an interval
[0,τ] if for any ε > 0, φ ∈ C([−r,0];R3) and final state z1 ∈ R3 there exists a control v ∈
C([0,τ];R2) such that the corresponding solution of system (4.6) satisfies two conditions:
1. z(0) = φ(0)
2. ‖z(τ)− z1‖ < ε







A(t−s) f (zs(−r))ds, t ∈ [0,τ]
z(s) = φ(s), s ∈ [−r,0]
To assist proving the approximate controllability of system (4.6), the Gramian matrix of
the linear system (4.4) must be defined. Where the Gramian matrix definition is given by:
Definition 4.3.2. Given a set of vectors v1, v2,. . .,vn. The Gramian matrix or the Gram





, i, j ∈ 1,2, ...,n







The solution of system (4.4) at any time t = τ with initial condition z(t0) = z0 is given by:










T (τ−t)W−1t0 (z1− e
Aτz0), ∀t ∈ [t0,τ]
As shown by,


















= eAτz0 + z1− eAτz0
= z1
After defining the approximate controllability of system (4.6) and the Gramian of the
linear system (4.4) the proof can be done.
Theorem 4.3.2. The semilinear system with delay (4.6) is approximately controllable on
[0,τ].
Proof. For a given φ ∈ C([−r,0];R3), a final state z1 and ε > 0, it is required to find a
controller v ∈C([0,τ];R2) such that the corresponding solution zv(.) of (4.6) satisfies:
‖z(τ)− z1‖< ε
A fixed control v ∈ C([0,τ];R2) is considered with a corresponding solution z(t,φ ,v) =
z(t). Then, a number δ is considered such that is small enough so that δ < r < τ and the
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control is defined by:
vδ (t) =

v(t), i f 0 < t < τ−δ
vτ−δ (t), i f τ−δ < t ≤ τ
where,
vτ−δ (t) = BT eA
T (τ−t)W−1
τ−δ (z1− e
Aτz(τ−δ )), τ−δ ≤ t ≤ τ
The solution of (4.6) corresponding to the control vδ (t) denoted by zδ (t) is given by:







Evaluating zδ (t) at t = τ and taking eAδ as a common factor, the following is obtained:





















The expression is simplified to get:














After moving z1 to the other side, the expression can be represented by:






Then, by taking the norm, the following inequality is obtained:
∥∥∥zδ (τ)− z1∥∥∥≤ ∫ τ
τ−δ




Since zδ (s− r) = z(s− r), if τ−δ ≤ s≤ τ , then
∥∥∥zδ (τ)− z1∥∥∥≤ ∫ τ
τ−δ
M ‖F(z(s− r))‖ds
Take K = max
s∈[0,τ]
{∥∥∥eA(τ−s)∥∥∥‖F(z(s− r))‖} and δ < min{r, εK} to get:
∥∥∥zδ (τ)− z1∥∥∥< ε
4.3.2 Exact Controllability
The exact controllability of system (4.2) is going to be proved without the inclu-
sion of a time delay. However, it will still involve a slight modification in the system.
The proof employs the Banach contraction mapping theorem which is also known as the
Banach fixed point theorem which has the following definition:
Definition 4.3.3. Let X be a complete metric space and T : X −→ X be a contraction
map, meaning, there exists a constant q ∈ (0,1) such that d(T (x),T (y)) ≤ qd(x,y) for all
x,y ∈ X . Then, there exists a unique point z, such that T (z) = z. In other words, T has a
fixed point [39].
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System (4.2) can be written in the following slightly altered way:
dG
dt = −m1G−m5X +X(m5−G)+ J
dX
dt = −m2X +m3I
dI
dt = −m4I +u
(4.7)

























Before proving the exact controllability of system (4.8), it is favored to start by proving
the following corresponding linear system:
ż(t) = Az+Bv, t ∈ (0,τ] (4.9)
Proposition 4.3.3. The linear system (4.9) associated with the semilinear system (4.8) is
exactly controllable on the interval [0,τ].
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Hence, system (4.9) is exactly controllable on any time interval.
Before proving the exact controllability of system (4.8) the following operators of the
corresponding linear system (4.9) needs to be defined:













◦ The adjoint G∗ : R3→ L2(0,τ;R2) is given by
(G∗(ζ ))(t) = BT eA
T (τ−t)ζ
It can be noted that the Gramian operator is a combination of the controllability operator
G and its adjoint G∗, i.e.







Now, the exact controllability of system (4.8) can be proved.
Theorem 4.3.4. Under some conditions the semilinear control system (4.8) is exactly
controllable on the interval [0,τ].
Proof. Firstly, system (4.8) is assumed to be exactly controllable on the interval [0,τ].
Then, for any initial and final states z0,z1 ∈ R3, there exists a control v ∈ C([0,τ];R2)
such that the corresponding solution of (4.8) satisfies:




















































Now, an operator L is defined by:










Then, the solution of the initial value problem (4.8) can have the following representation:







Which motivates the definition of the following operator:
P : C([0,τ];R3)−→C([0,τ];R3)
That is defined by the following expression:







Hence, the controllability problem is reduced to the problem of finding a fixed point for













0 M ‖L (z2)(s)−L (z1)(s)‖ds
+
∫ t






The inequality ‖F(z2)−F(z1)‖ ≤ m5 ‖z2(s)− z1(s)‖ can be proved directly by substitut-
ing the expression of F(z). On the other hand,
‖L (z2)(s)−L (z1)(s)‖ ≤ ‖Γ‖
∫
τ
0 Mm5 ‖z2(s)− z1(s)‖ds










∥∥W−1∥∥m5τ2 + τm5M)(‖z2− z1‖)
‖P(z2)−P(z1)‖ ≤ (‖B‖M2
∥∥W−1∥∥τ +1)τm5M ‖z2− z1‖
Consequently, P is contraction map in case the following condition holds:
(‖B‖M2
∥∥W−1∥∥τ +1)τm5M < 1
Accordingly, the following theorem is deduced:

















To furtherly emphasize theorem (4.3.5), the following example is presented using
parameter values obtained from the original paper [21] that presented bergman’s model.






































τ +1)τm5M = 0.989347 < 1
So, the inequality of Theorem (4.3.5) is satisfied. Therefore, system (4.8) in this case is
exactly controllable on the time interval [0,60]. Note that for the system to be exactly con-
trollable, the value of m5 should be selected based on the value of τ . For instance, in case
τ = 60 minutes then any positive value of m5 such that m5 ≤ 1.8∗10−12 would satisfy the
inequality. However, if the value of τ is increased to 120 minutes, then m5 = 1.8∗10−12
would no longer satisfy the inequality and values of m5 such that m5 ≤ 4.5∗10−13 would
satisfy the inequality. Which means that in order to satisfy the inequality of Theorem
(4.3.5) the value of m5 should be decreased as the value of τ increases. Practically speak-
ing, if the time τ to control the blood glucose level was to be increased, then the value of
m5 should be decreased, which implies that it would require more number of digits to be
presented. This implies that the precision of the control system should increase to fit more
number of digits as the controlling time increases. Hence, it would be preferred to use




Just like in the case of controllability. First, the observability of the linear system
corresponding to system (4.2) is proved. This linear system has the following form:
ż = Az+Bv (4.10)
y = Hz (4.11)















Rank(O) = 3−→ system (4.10) is observable on any time interval according to Kalman’s
Rank Condition [29, 30].
To prove the observability of the semilinear system (4.2), system (4.2) is considered to be
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independent of the control variable, i.e.
ż = Az+F(z) (4.12)
Then, the observability is proved directly using the following theorem from [40].
Theorem 4.3.6. Assume that the transformations f : R3 −→ R3 and h : R3 −→ R3 to be
continous. If the pair ( fz(0),hz(0)) is observable, then the system (5.11) is observable at
any time t > 0 [40].
Where the transformations f and h are defined as follows:
f (z) = Az+F(z)
h(z) = Hz
Then, ( fz(0),hz(0)) = (A,H). and since the linear system (4.10) is observable, then the
semilinear system (4.2) - (4.3) is observable at any time t > 0, which is clearly true since
the blood glucose level can be observed at any time through the CGM.
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Chapter 5: Literature Review - Modeling of Infectious Diseases
5.1 Compartmental Disease Transmission Models
Mathematical modeling of infectious diseases is a powerful tool to study the
spread of an infectious disease. These models can predict the progression of the disease
spread, and they can also determine the key factors that contributes to the disease trans-
mission making them a helpful tool in the development of the strategies that aids in the
prevention and control of the disease spread [41].
These models are known as the Compartmental Disease Transmission Models.
As the name suggests, in these models the population of concern is divided into compart-
ments where each individual is characterized by a distinct state variable. In other words,
no individual can be present in more than one compartment. A compartment can either be
a disease compartment containing both symptomatically and asymptomatically infected
individuals, or a non-disease compartment containing non diseased individuals [42].
In this case, the total population at issue is divided into n disease compartments and m
non-disease compartments, then the disease transmission model can be written in the
following form of a system of ODEs [42]:
x′i = Fi(x,y)−Vi(x,y), i = 1,2, ...,n
y′j = G j(x,y), j = 1,2, ...,m
Where xi, for i ∈ 1,2, ...,n represents a disease compartment, and y j, for j ∈ 1,2, ...,m
represents a non-disease compartment. Moreover, Fi represents the rate of increase of
secondary infection in the disease compartment i, and Vi represents the rate of decrease
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in the compartment i either by disease progression, recovery, or death.
5.2 SEIR Model
An example of a compartmental disease transmission model is the SEIR model.
This model segregates the population of concern into four sub populations. Namely, sus-
ceptible or vulnerable population (S), Exposed or latent infected population (E), infectious
population (I), and recovered population (R). This model assumes that all new infections
takes place at the first stage when a susceptible individual comes into contact with an
infected individual. SEIR models can be presented in may possible ways, one of which is
written as follows [42]:
S′ = Π−µS−βSI
E ′ = βSI− (µ +κ)E
I′ = κE− (µ +α)I
R′ = αI−µR
Naturally, all initial conditions are non negative, since the number of individuals
in a population cannot be negative. This representation assumes that the natural birth rate
of susceptible persons is a constant Π. On the other hand, natural death rate is assumed
to be µ for all the sub populations. The rate at which new infections emerges into the
exposed sub population is βSI. Exposed individuals become infectious by the rate κ , and
infected individuals recovers at the rate α .
It is to be noted that not all SEIR models have the presented form. Some of
which neglects the natural birth and death rates. In addition, the presented model assumes
that individuals gets immunity after recovery. However, some models assumes that the
recovered individuals progresses to become susceptible again at a certain rate.
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Figure 5.1 shows a flow chart of the presented SEIR model.
Figure 5.1: Flow diagram of an SEIR model
5.3 The Basic Reproduction Number
Definition 5.3.1. The basic reproduction number R0 can be defined as the expected num-
ber of secondary infection cases produced directly by a single infectious individual as-
suming that the population is susceptible [43].
In other words, R0 is a measure of the potential of an infectious disease to spread
in a population. If R0 < 1, then the number of infection cases will decay until the disease
vanishes from the population. On the other hand, in case R0 > 1, then the disease is going
to persist [43].
5.3.1 Basic Reproduction Number Calculation
For a compartmental ODE disease transmission model, R0 could be calculated by the
following steps [42]:
1. Firstly, The system of ODE of disease compartments is represented in the following
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form:
Ẋ = F −V
Where F ∈Rn represents secondary infections, and V ∈Rn represents disease pro-
gression, recovery, or death.
2. Secondly, Ẋ is linearized about the disease free equilibrium point to get the following
decoupled form:
Ẋ = (F−V )X
Where the infection matrix F , and the transition matrix V are n×n matrices whose







3. Lastly, the next generation matrix K = FV−1 is calculated, and R0 is simply the
eigen value of K with the biggest modulus.
5.4 Sensitivity Index
In a model, to measure the relative change of a variable with respect to a parameter the
sensitivity index of that variable with respect to the parameter is calculated. If the variable
is differentiable with respect to the parameter, then the sensitivity index can be calculated








Were x is the variable, and θ is the parameter.
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Chapter 6: The Impact of COVID-19 on Patients with Comorbidity
6.1 Problem Statement
Individuals with diabetes have weakened immune functions. As a result, diabetic
individuals were found to be at more risk of becoming critically ill when infected with a
viral or bacterial infection as witnessed in the previous pandemics including SARS-CoV-
1, H1N1, and MERS [45]. This was also found in the case of COVID-19 as suggested
by many reports and studies. For instance, The Chinese Center for Disease Control and
Prevention reported that the fatality rate of diabetic COVID-19 patients was 7.3% based
on a report of 44,672 patients. Another study showed that 72% of COVID-19 patients
with comorbidities including diabetes required admission to an ICU according to a study
of 139 patients [45]. More generally, COVID-19 patients with not only diabetes, but other
comorbidities such as cardiovascular diseases ,hypertension, lung diseases and kidney
diseases were found to constitute the majority of higher morbidity and fatality cases [46,
47, 48].
As mentioned in Chapter 1, COVID-19 is a highly transmissible disease with
many asymptomatic infection cases, making this disease very difficult to control and man-
age, and especially dangerous for the comorbidity population. Since the disease is highly
contagious and is rapidly transmitting, it is crucial to find a way to control the spread of
this disease. Mathematical modeling is a possible method to rapidly analyze the disease
spread and develop a strategy to control it [49].
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6.2 Thesis Contribution
The second part of this thesis presents a COVID-19 compartmental disease trans-
mission model in the form of a system of ODEs. As previously stated, individuals with
comorbidities are medically vulnerable, and so they are at a greater risk of developing
critical disease complications in case they get infected, and they also have a higher fa-
tality risk due to this contagious disease. Consequently, the presented model is focused
on the populations of comorbidity. This model is an extended SEIR model that divides
the population into: susceptible (S), exposed (E), mildly infected (I), asymptomatically
infected (A), and treated populations (J) with and without comorbidity. It also includes
the recovered (R), critically ill infected (C), and fatality populations (D).
The model can be used to represent the population of any city, country, or region.
This can be done by estimating the parameters after fitting the model into the real data
of the number of active infection cases in the desired population. In the presented case,
the model is made to represent the population of the United Arab Emirates Country. The
considered timeline is between the 22nd of January 2020 until the 27th of June 2020.
Calculations of the basic reproduction number are included. These calculations
will help get an insight on how rapid the disease is being transmitted. Additionally, cal-
culations of the sensitivity indices of the basic reproduction number with respect to the
model’s parameters are calculated. With the help of the sensitivity indices, the major fac-
tors that contributes to the disease transmission can be determined. Hence, by utilizing
the calculations obtained, disease transmission control strategies can be developed.
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6.3 Disease Transmission Model of COVID-19
The proposed mathematical model of the transmission of COVID-19 is given by the fol-
lowing system of ODEs:




























Ȧ1 = γ1E1− (κ1 +ϕ1 +αA1)A1
Ȧ2 = γ2E2− (κ2 +ϕ2 +αA2)A2
İ1 = κ1A1 +ν1E1− (ξ1 +αI1)I1
İ2 = κ2A2 +ν2E2− (ξ2 +αI2)I2
J̇1 = ϕ1A1 +ξ1I1−αJ1J1
J̇2 = ϕ2A2 +ξ2I2− (η +αJ2)J2
Ṙ = αA1A1 +αA2A2 +αI1I1 +αI2I2 +αJ1J1 +αJ2J2 +αCC
Ċ = ηJ2− (µ +αC)C
Ḋ = µC
(6.1)
Sub populations: In this compartmental ODE model, the populations S, E, A, I,
and J are indexed by either 1 or 2. Index 1 represents a population without comorbidity,
while index 2 represents a population with comorbidity. The recovered population R
includes all individuals that have recovered with and without comorbidity. It is assumed
that only individuals with comorbidity can develop a critical condition due to COVID-
19. Therefore, the population C only includes individulas with comorbidities. Likewise,
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it is also assumed that death due to COVID-19 only constitutes comorbidity population.
Hence, population D is the fatality population of those who were infected with COVID-19
with a comorbidity. Since the considered timeline is somewhat short, the total population
N is considered to be constant, i.e.
N = S1 +S2 +E1 +E2 +A1 +A2 + I1 + I2 + J1 + J2 +C+R+D = constant
Infection: In this model, it is assumed that new infection cases arise when a sus-
ceptible individual from S1 or S2 comes into contact with either a mildly infected individ-
ual from I1 or I2, or an asymptomatically infected individual from A1 or A2. It assumed
that infected people who are being treated from J1 or J2 do not cause any secondary infec-
tions as they are isolated in a hospital. The same situation applies for infected individuals
with a critical condition from C.
Parameters: parameters of the form β xy represents the disease transmission rate
from an individual of population y to an individual from population x. The parameters γ
and ν represents the rate at which an exposed individual progresses from the exposed class
to the asymptomatic and the mildly infected classes respectively. The recovery rates are
represented by the α parameters. An individual with comorbidity that is under treatment
develops a critical condition at the rate η , and an individual under critical condition has a
death rate of µ due to COVID-19 .
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Figure 6.1: Flow chart of COVID-19 transmission model
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6.4 Data Acquisition and Parameter Estimation
As a first step to estimate the model’s parameters, some key parameters of the COVID-19
pandemic were estimated using data from china, the country with the first reported cases
of the disease. These estimations are presented in Table 6.1.
Table 6.1: Estimations of key parameters of COVID-19
Parameter Symbol Value (s) Reference (s)
Fraction of asymptomatic
infections FracA 20 - 40% [50, 51, 52, 53]
Duration of the infectious




infections (days) DurA 4 - 9.5 [54]
Average incubation period
(days) IncPer 4 - 9
[50, 55, 56, 57, 58]
[59, 60]
Average duration of mild
infections DurMInf 4 - 20 [54, 60, 61, 46, 62]
Average fraction of mild
symptomatic infections FracMInf 27 - 81% [54, 58, 63]
Average fraction of severe
symptomatic infections FracSev 14 - 24 % [54, 58, 63]
Average fraction of critical
symptomatic infections FracCri 2 - 6% [54, 58, 63, 64]
Average hospitalization
duration (days) DurHos 8 - 23
[46, 64, 65, 66, 67]
[68, 69]
Average ICU admission
duration (days) TimeICU 21
Probability of death
due to the infection ProbDeath 0.04 - 7.71% WHO
Average time in the ICU
until death (days) TimeICUdeath 8 - 10 [62, 70]
Note: Since Model 6.1 is intended to represent the spread of COVID-19 in the United
Arab Emirates, the probability of death in Table 6.1 is based on the COVID-19 fatality
percentages of some of the Arab countries obtained from data provided by WHO during
the considered period.
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For the second step, the model’s parameters were given initial estimated values that are
calculated based on the COVID-19 parameters presented in Table 6.1. These initial values
are presented in Table 6.2.
Table 6.2: The estimated parameter values
Parameter Symbol Value for i = 1 Value for i = 2
Rate of progression from exposed
to asymptomatic class γi 0.5 0.5
Rate of progression from exposed
mild symptoms class νi
1
7 0.5
Rate at which the asymptomatic
develops mild symptoms κi 0.2025
27
950
Rate at which the asymptomatic
becomes hospitalized ϕi 0 0








Recovery rate of an infected
individual with mild symptoms αIi 0.043 0.1825
Rate at which a hospitalized individual
develops a critical condition η -
3
1150
Recovery rate of hospitalized
infected population αJ 0.1225
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1150
Recovery rate of an infected individual
in the ICU αC - 0.04395
Death rate of an individual
in the ICU µ - 0.00964
Infection rate by a mildly
infected individual β
i
I j 0.5944 1.68
Infection rate by an asymptomatically
infected individual β
i
A j 0.5944 1.68
Note: the mathematical formulas used to calculate these parameters are presented in the
Appendix in Table 6.
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Thereafter, real data of the active infection cases in the United Arab Emirates were ob-
tained from the 22nd of January 2020, to the 27th of June 2020. These numbers were
obtained by subtracting the number of the recovery and death cases from the accumulated
number of infection cases obtained from the World’s Health Organization. Plots of the
accumulated, recovered, death and active infection cases are presented in Figure 6.2 and
Figure 6.3.



















Figure 6.2: Active, recovered and accumulated infection cases in the UAE


















Figure 6.3: Death cases in the UAE
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Next, using MATLAB, Model 6.1 was fitted to the real active infection cases as shown in
Figure 6.4.



































Fitness of model with data of UAE
 
 
Approximative declared infection cases
Declared active infection cases
Figure 6.4: Fitting model’s infection cases with real infection cases
The active infection cases of the model were considered to be:
active infection cases = A1 +A2 + I1 + I2 + J1 + J2 +C
Note: The exposed populations E1, and E2 were not considered as active infection cases
as they include latently infected individuals whose infection is not active and they are not
yet infectious.
The fitted parameters values are presented in Table 6.3.
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Before analyzing the spread of COVID-19 in the United Arab Emirates, the basic repro-
duction number is calculated as it is needed for the analysis.
6.5 The Basic Reproduction Number
The infection compartments are represented by the disease state vector ~X which is ex-
pressed as:
~X = [ E1 E2 A1 A2 I1 I2 ]
T
































−γ1E1 +(κ1 +ϕ1 +αA1)A1




After linearizing the model about the disease-free equilibrium point, the following decou-
pled form is obtained:
Ẋ = (F−V )X
Where the infection matrix F is given by:
F =































0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0

Here, So1 and S
o
2 denotes the disease-free equilibrium populations with and without co-
morbidity.
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The transition matrix V is given by, V =

(γ1 +ν1) 0 0 0 0 0
0 (γ2 +ν2) 0 0 0 0
−γ1 0 (κ1 +ϕ1 +αA1) 0 0 0
0 −γ2 0 (κ2 +ϕ2 +αA2) 0 0
−ν1 0 −κ1 0 (ξ1 +αI1) 0
0 −ν2 0 −κ2 0 (ξ2 +αI2)

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This indicates that R0 depends on four components which can be viewed as sub ba-
sic reproduction numbers. R01 represents the basic reproduction number of the non-
comorbidity population on its own, R02 represents the basic reproduction number of the
comorbidity population, R̄01 represents the basic reproduction number of the infection
of the non-comorbidity population that is caused by the comorbidity population and R̄02
represents the basic reproduction number of the comorbidity population infections which
are caused by the non-comorbidity population. Hence, different population distributions
results in different reproduction numbers as indicated by the following scenarios:
Case 1: R̄01 = 0
In this case no infection of the general population is caused by the comorbidity
population. This is achieved by isolating individuals with comorbidity from the
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(R01−R02)2 +R01 +R02) = R01
indicating that infection will only be spread among the non-comorbidity population
and the disease will not be transmitted from or to the comorbidity population. In
this scenario the following points can be drawn:
R0 > 1: when R01 > 1
R0 < 1: when R01 < 1
Indicating that disease transmission depends completely on the general population.
Case 2: R̄02 = 0
In this case no disease transmission from the general population to the comorbidity
population takes place. This case has the same result as case 1.
Note: The previous two cases are examples of shielding which is a method utilized
by the governments of many countries to prevent disease spread amongst people
who are medically vulnerable. These people includes elderly, people suffering from
heart or respiratory diseases in addition to pregnant women. In this method, these
people isolate themselves and practice social distancing as much as possible in order
to protect themselves.
Case 3: R01, R02, R̄01 and R̄01 are constants. In this case the disease is being transmitted in










(R01−R02)2 +4R̄01R̄02 < 2−R01−R02
in case
|R01−R02|< 2−R01−R02
which applies when max{R01,R02}< 1, implying that the disease will stop spread-
ing once it stops spreading amongst both the general and the comorbidity popula-





(R01−R02)2 +4R̄01R̄02 +R01 +R02)> 1,
which implies that
√
(R01−R02)2 +4R̄01R̄02 > 2−R01−R02
which applies when min{R01,R02}> 1 indicating that the disease will continue to
spread as long as it is still spreading amongst both the general and the comorbidity
populations.
6.6 Analyzing the Spread of COVID-19 in the UAE
In this section, the spread of COVID-19 in the United Arab Emirates is analyzed
using Model (6.1). The considered timeline is from the 22nd of January 2020, to the
27th of June 2020. In the model, the 22nd of January is denoted by t = 0, and the
27th of June 2020 is denoted by t = 157, where t represents the days.
61
Stages of measures: The considered timeline can be divided into three stages
based on the measures the authorities of the United Arab Emirates took to help in
reducing the spread of COVID-19. These stages are given by:
Stage 1 (No intervention): This stage was at the beginning of the pandemic. Hence,
the number of cases was not significant. The country’s authorities observed the
evolution of the infection cases in this stage and started to prepared a proper
strategy for reducing the spread of COVID-19. At this stage, the transmission
rate can be considered to be constant.
Stage 2 (Slightly effective intervention): At this stage, the number of cases has signifi-
cantly increased. Hence, the concerned authorities used a series of measures to
help reducing the spread of COVID-19. These measures included switching to
remote working for applicable jobs, in addition to virtual learning for students.
Moreover, many malls and shops were temporarily closed and a nationwide dis-
infection program was established [71]. These measures helped in relenting the
spread of COVID-19 but were not very effective, as the number of active infec-
tion cases continued to rise. At this stage, the transmission rate was reduced,
but can also be considered to be constant.
Stage 3 (Effective intervention): At this stage, authorities imposed a full lock-down on
the country. This measure led to a significant decrease in the mobility of people
in the UAE as indicated by Apple’s and Google’s mobility reports [72, 73].
Naturally, the transmission rate has decreased at this stage, and the number of
active infection cases have started to decrease as well.
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Figure 6.5 shows the three mentioned stages represented by an active infection case
timeline.


















Figure 6.5: The three stages of measures taken by the UAE authorities
Approximating disease-free equilibrium populations: At the disease-free
equilibrium, the population with comorbidity So2 is approximated by the population
aged 55 years old and above. This approximation is based on a study on the severity
of COVID-19. In this study, data were collected from the different regions of china
including Wuhan where the virus is originated. The study showed that the fatality
rate is higher amongst the populations aged 50 and above [69].
In the UAE, the population aged 55−64 makes up 7.68% of the total popu-
lation, and the population aged 65 years and above makes up 1.9% of the total pop-
ulation, meaning that the population with comorbidity is approximated by 9.58%
of the total population of 9,992,083 as in july 2020 [74]. Hence, So2 ≈ 957242 and
So1 ≈ 9034841. The comorbidity percentage is denoted by p = 9.58%.
Using a similar method, the number of people with comorbidity in the different
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subpopulations can be approximated. For simplicity, it is presumed that β 1I1 = β
2
I1 ,










A2 , which means that an individual in the same class
of infection has the same transmission rate (mobility).
The transmission rate of the asymptomatic individuals depends on their mo-
bility, where infected individuals of this category do not show any symptoms, and
therefore infect others without being revealed. Individuals of this category consti-
tutes most of the careless individuals who does not respect the restrictions imposed
by the government. Using the mobility reports [72, 73] it can deduced that there
is a decrease of 55− 60% in the mobility at parks. Implying that 40− 45% of the
population did not respect the measures taken by the government. Hence, the mo-





i, j = 1,2. Now it remains to determine the transmission rates β 1Ii , i = 1,2.





βi, t ∈ [0,100] (Stage 1)
38.5%βi, t ∈ [100,140] (Stage 2)
38.5%βi exp−δ t , t ∈ [145,157] (Stage 3)
(6.2)
where δ = 0.0265 denotes the lock-down efficiency rate. Using these approxima-
tions, it is deduced that: β1 = 2.1×10−8 and β2 = 4×10−9.
Using the approximated parameter values of Model 6.1 in Table 6.3, and the approx-
imated transmission rates, the number of individuals in each infection class can be
approximated as shown in the following timeline.
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Figure 6.6: Infection cases in each class
By taking a closer look at Figure 6.6, one can note that the number of the mildly
infected individuals without comorbidity (I1) is far greater than the one with co-
morbidity (I2). The same remark can be noted for the A and E classes. This is a
very important remark as it indicates that the UAE community have implemented a
shielding behavior that isolates the comorbidity population in order to protect them.
Now, using the previously mentioned approximations the following values are ob-
tained:
φ1 = 3.1111, φ5 = 4
φ2 = 17.0444, φ6 = 16.2
φ3 = 4.75, φ7 = 9.5
φ4 = 2.6186, φ8 = 1.1134
Therefore, the values of R0 corresponding to the three stages are given by:
Table 6.4: R0 on the different stages
Stage 1 Stage 2 Stage 3
R0 = 3.4873 R0 = 1.3426 R0 = 0.0288−0.0209
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6.7 Sensitivity Analysis
Sensitivity analysis helps in determining how important each parameter is to
disease transmission. Such an analysis is commonly used to determine how robust
a model is to the predicted parameter values, since data collection and presump-
tions are usually accompanied with errors. Using the sensitivity index, parameters
that have a high impact on R0 can be determined, and by using this knowledge
an appropriate intervention strategy to help in reducing disease transmission can be
implemented [44].
The sensitivity index of R0, which is differentiable with respect to a given parameter









The sensitivity index expressions of R0 with respect to the parameters of Model 6.1
are presented in the Appendix, and the values of these indices are presented in Table
6.5.
Looking at the sensitivity indices in Table 6.5, it can be noticed that all















itive sensitivity indices, which indicates that clearly when disease transmission is
increased, naturally the basic reproduction number will increase accordingly. Sim-
ilarly, the recovery rates αI1 , αI2 , αA1 and αA2 have negative sensitivity indices,
indicating that when the recovery rates increase, the basic reproduction number will
decrease in response.
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Note: The sensitivity indices of the parameters αJ1 , αJ2 , η and µ are zero since R0


















































Figure 6.7: Sensitivity index bar chart
Figure 6.7 shows the sensitivity indices that has the most effect on R0. The values
of the sensitivity indices indicates that β 1I1 , and αI1 are the parameters that effects
the value of R0 the most, where β 1I1 has an index of +0.8890, and αI1 has an index
of −0.7828. Indicating that when β 1I1 increases by 100%, R0 increases by 88.9%
as a response. Similarly, when αI1 increases by 100%, R0 decreases by 78.28%
accordingly.
6.8 Results and Discussions
Using Model 6.1 with its parameters, the following conclusions can be drawn :
1. The speed of the transmission of COVID-19 is determined by R0. More-
over, since the stages with authority intervention had a smaller number of R0,
then this indicates that clearly imposing lock-down / quarantine measures helps
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greatly with reducing the transmission rate of COVID-19.
2. The parameters / factors with the major effects on R0 were the disease trans-
mission and the recovery rates. This indicates that practicing social distancing
to minimize contact between people, and enhancing the immune system to in-
crease the recovery rate are the best solutions to reduce the speed of the disease
spread and consequently diminish it.
However, the social distancing solution has its flaws. Firstly, it has a negative impact
on the economy. This results from the fact that remote working is not as productive
as working at the workplace. Additionally, many restaurants, hotels and gyms were
bankrupt as they received little to no customers. Secondly, as for education, many
students experienced difficulties with virtual learning as they cannot learn as effi-
ciently, resulting in bad academic performance.
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The mathematical formulas that have been used to calculate the initial parameter
estimations of Model 6.1 are presented in Table 6.6.
Table 6.6: Formulas of the estimated parameter values
Parameter Mathematical Formula
γi, i = 1,2 1/PresPer
νi, i = 1,2 1/( IncPer-PresPer)
κi, i = 1,2 (1/DurA)FracMInf
ϕi, i = 1,2 0
αAi, i = 1,2 (1/DurA)(1−FracMInf)
ξi, i = 1,2 (1/DurMInf)FracSev
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Note: The sensitivity indices of the remaining parameters are zero since R0 doesn’t
depend on them.
